Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults by Shin, Andrea et al.
1Shin A, et al. BMJ Open Gastro 2019;6:e000322. doi:10.1136/bmjgast-2019-000322
Associations of chronic diarrhoea with 
non-alcoholic fatty liver disease and 
obesity-related disorders among 
US adults
Andrea Shin,   1 Huiping Xu,2 Thomas F Imperiale1,3
To cite: Shin A, Xu H, 
Imperiale TF. Associations 
of chronic diarrhoea with 
non-alcoholic fatty liver 
disease and obesity-
related disorders among US 
adults. BMJ Open Gastro 
2019;6:e000322. doi:10.1136/
bmjgast-2019-000322
Received 14 June 2019
Revised 16 July 2019
Accepted 24 July 2019
1Division of Gastroenterology 
and Hepatology, Department 
of Medicine, Indiana 
University School of Medicine, 
Indianapolis, Indiana, USA
2Department of Biostatistics, 
Indiana University School of 
Medicine, Indianapolis, Indiana, 
USA
3Center of Innovation, Health 
Services Research and 
Development, Richard L. 
Roudebush Veterans Affairs 
Medical Center, Indianapolis, 
Indiana, United States
Correspondence to
Dr Andrea Shin;  ashin@ iu. edu
Colon
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
Summary box
What is already known about this subject?
 ► Diarrhoea and accelerated intestinal transit are as-
sociated with obesity or increased body mass index 
(BMI); however, the factors that explain these asso-
ciations are unclear.
 ► Despite the well-described association between 
diarrhoea and obesity, there are limited popula-
tion-based data that have examined the correlation 
between bowel habits and specific obesity-related 
disorders such as metabolic syndrome (MS) and 
non-alcoholic fatty liver disease (NAFLD).
What are the new findings?
 ► In this population-based analysis, MS was more 
common in those with diarrhoea, but this associa-
tion was not independent of BMI.
 ► Prevalence of NAFLD was higher in those with di-
arrhoea than in those with constipation or normal 
bowel patterns, and this association was indepen-
dent of BMI.
How might it impact on clinical practice in the 
foreseeable future?
 ► A potential independent link between NAFLD and 
diarrhoea may influence our clinical approach to 
patients who suffer from these two highly prevalent 
conditions.
 ► Further prospective study of potentially shared 
mechanisms between diarrhoea and NAFLD is 
warranted.
ABSTRACT
Mechanisms explaining observed associations between 
diarrhoea and obesity or increased body mass index (BMI) 
are unclear.
Objective To assess associations of bowel patterns with 
BMI, metabolic syndrome (MS), non-alcoholic fatty liver 
disease (NAFLD) and other obesity-related disorders.
Design We performed a cross-sectional analysis of data 
from adults who completed bowel health questions for the 
2005 to 2010 cycles of the National Health and Nutrition 
Examination Surveys. Relationships were examined using 
multinomial logistic regression. Confounding effects of 
demographics, smoking, alcohol and BMI were examined 
by sequential modelling.
Results Among 13 413 adults, weighted prevalence 
rates of constipation and diarrhoea were 8.9% and 
6.6%, respectively. Mean BMI was associated with bowel 
patterns (p<0.001), and was higher with diarrhoea (30.3 
kg/m2) versus normal bowel patterns (28.6 kg/m2) and 
with diarrhoea versus constipation (27.8 kg/m2). NAFLD 
was more prevalent (ORs, 95% CI) in diarrhoea versus 
normal bowel patterns (OR=1.34, 95% CI 1.01 to 1.78) 
or constipation (OR=1.45, 95% CI 1.03, 2.03) in adjusted 
analyses. The higher prevalence of MS in diarrhoea versus 
constipation (OR=1.27, 95% CI 0.97 to 1.67) was not 
independent of BMI.
Conclusions These findings suggest an association 
between diarrhoea and NAFLD that is independent of BMI.
IntroductIon
Functional bowel disorders such as irritable 
bowel syndrome (IBS) and functional diar-
rhoea are highly prevalent worldwide.1 An 
increased prevalence of diarrhoea has been 
reported in obese individuals. Multiple 
studies have linked diarrhoea and acceler-
ated intestinal transit2 with obesity,3 4 and 
high body mass index (BMI).5 6 Others have 
reported potential associations between IBS 
or chronic diarrhoea and obesity-related 
disorders such as metabolic syndrome (MS) 
and associated conditions such as non-al-
coholic fatty liver disease (NAFLD).7 8 In a 
previous cross-sectional study, IBS was associ-
ated with higher anthropometric measures, 
higher transaminase, gamma-glutamyl 
transferase and lipid levels compared with 
controls.7 The mechanisms explaining these 
associations are yet unclear, although some 
hypothesise a connexion with eating habits 
and gastrointestinal (GI) motility.9 Factors 
such as altered bile acid homeostasis,10 the GI 
microbiome, or increased intestinal permea-
bility11 may also contribute to associations 
between lower GI symptoms and obesity.
There are limited population-based data 
examining associations between bowel habits 
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and the comorbid conditions associated with overweight 
or obesity. Understanding the strength of these poten-
tial associations could have important implications for 
clinical management and evaluation of patients with 
abnormal bowel patterns, and may help generate new 
hypotheses on the mechanisms that link GI symptoms 
with BMI or obesity. Thus, the aims of this study were (1) 
to assess the association between BMI and bowel patterns 
and (2) to determine if MS or other obesity-related disor-
ders are associated with bowel patterns independent of 
BMI. Investigating relationships between bowel patterns 
and MS or other obesity-related disorders may provide 
further insight into common pathophysiological mech-
anisms or identify previously unrecognised associations 
that could impact the future care of patients experi-
encing these common disturbances in bowel function.
Methods
study population
The National Health and Nutrition Examination Surveys 
(NHANES) is a programme conducted by the National 
Center for Health Statistics of the Center for Disease 
Control and Prevention12 designed to assess health and 
nutritional status of civilian non-institutionalised persons 
in the USA through a complex, multistage probability 
sampling design. Since 1999, it has been a continuous 
survey programme examining a representative sample of 
approximately 5000 people per year across the country 
with over-sampling of specific age and ethnic groups. The 
protocol for NHANES 2005 through 2010 was approved 
on 18 March 2005 and annually thereafter by the National 
Center for Health Statistics research ethics review board 
in accordance with federal regulations (45 CFR 46.111) 
and ethical guidelines of the Declaration of Helsinki 
(adopted in 1964 and subsequently revised many times). 
Signed consent was obtained from all participants. The 
analytic sample included participants with available stool 
type in any of the three NHANES cycles (2005–2006, 
2007–2008 and 2009–2010). Combining data across 
2-year cycles based on 4 or more years of data will produce 
estimates of greater precision, and is recommended in 
the guidelines published by NHANES.12 Participants with 
opioid-induced constipation, defined based on previ-
ously published reports13 and those with missing data for 
relevant variables were excluded.
Bowel health questionnaire
We utilised data from adult participants >20 years old 
who completed the bowel health questionnaire (BHQ). 
BHQ questions were completed in a mobile examination 
centre using a computer assisted personal interviewing 
system. Stool consistency was assessed using the Bristol 
Stool Form Scale (BSFS).14 In all three NHANES cycles, 
participants were asked to report weekly bowel move-
ment frequency (eg, how many times per week do you 
usually have a bowel movement) and most common stool 
type using the BSFS (eg, please look at this card and tell 
me the number that corresponds to your usual or most 
common stool type). In NHANES 2009, the BHQ was 
expanded to assess self-reported constipation and diar-
rhoea in the last 12 months. (eg, During the past 12 
months, how often have you been constipated/have you 
had diarrhoea?)
Lower GI symptom groups
Based on BHQ responses, participants were classified as 
having: (1) constipation, (2) diarrhoea and (3) normal 
bowel patterns. Categories were guided by Rome IV 
criteria for diarrhoea-predominant and constipation-pre-
dominant IBS, functional diarrhoea and functional 
constipation,1 although the specific criteria were not 
applied. Constipation was defined by: (1) most common 
stool type of 1 or 2 using the BSFS; (2) less than three 
bowel movements per week; or (3) always/most of the 
time have been constipated in the last 12 months. Diar-
rhoea was defined by: (1) most common stool type 6 or 7 
using the BSFS or (2) diarrhoea reported as always/most 
of the time in the past 12 months. Normal bowel patterns 
were defined by most common stool type 3–5 using the 
BSFS and bowel movement frequency ≥3 and <21 times 
per week. Definitions were established based on prior 
NHANES publications.4 15 16
demographics
Data were collected on demographic and socioeconomic 
variables: age; gender; race or ethnicity (non-Hispanic 
White, non-Hispanic Black, Mexican American/other 
Hispanic, or other); marital status (widowed, separated, 
divorced or married/cohabiting and never married); 
education level (less than high school education, high 
school diploma including general educational develop-
ment, or education beyond high school).
Anthropometric measures, blood pressure and labo-
ratory values: anthropometric measurements, blood 
pressure measurements and specimen collections for 
laboratory analyses were conducted in the mobile exam-
ination centre. Data were collected for fasting serum 
glucose (mg/dL), triglycerides (mg/dL), high-density 
lipoprotein (HDL) (mg/dL), low-density lipoprotein 
(LDL) (mg/dL) and total cholesterol (mg/dL).
Ms, nAFLd and obesity-related disorders
Participants with any three of the following five factors 
were considered to have MS as defined by the National 
Cholesterol Education Program Adult Treatment Panel 
III17: (1) elevated waist circumference (≥102 cm in men 
and ≥88 cm in women); (2) serum triglycerides >150 
mg/dL or drug treatment for elevated triglycerides; (3) 
serum HDL <40 mg/dL in men or <50 mg/dL in women; 
(4) blood pressure ≥130/85 mm Hg or drug treatment 
for elevated blood pressure; (5) elevated fasting glucose 
≥100 mg/dL or treatment for elevated blood glucose. 
Use of medications for blood pressure, cholesterol and 
blood glucose were ascertained by self-report. Consis-
tent with prior publications,18 participants with elevated 
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serum alanine aminotransferase or aspartate aminotrans-
ferase levels (males: aspartate aminotransferase >40 or 
alanine aminotransferase >37; females: aspartate amino-
transferase >31 or alanine aminotransferase >31) in the 
absence of excessive alcohol use or viral hepatitis (defined 
by a positive test for hepatitis B surface antigen or a posi-
tive hepatitis C antibody as in prior publications)18 were 
considered to have NAFLD. Additional comorbidities 
were ascertained by self-report and included: cardiovas-
cular disease (congestive heart failure, coronary heart 
disease, angina, heart attack, stroke), diabetes, sleep 
disorders (including sleep apnoea) and cancer. Diabetes 
was defined as being told of the diagnosis by a doctor/
health professional and/or taking insulin or other 
diabetic medication to lower blood sugar.
Additional covariates
Smoking history (never smoker; past smoker; current 
smoker) and alcohol consumption (lifetime abstinence; 
former drinker; moderate current drinker; or excessive 
drinker) as defined in prior publications19 were ascer-
tained. Excessive drinking was defined as >14 drinks 
per week for men, >7 drinks per week for women, or >5 
drinks per day in a single day at least once in the past 12 
months for either men or women.
statistical analysis
Data were summarised as means with 95% CIs for contin-
uous variables and proportions with 95% CI for cate-
gorical variables. Comparisons between bowel pattern 
groups were performed using analysis of variance for 
continuous variables and Rao-Scott χ2 test for categor-
ical variables. All analyses took into consideration of 
the complex sampling of NHANES incorporating the 
sampling weights and sample design.
Relationships between bowel patterns and MS, NAFLD, 
or other obesity-related disorders including cardiovas-
cular disease, diabetes, sleep disorder and cancer were 
examined using multinomial logistic regression through 
sequential modelling with a generalised logit link that 
controls for the potentially confounding effect of demo-
graphics, smoking, alcohol consumption and BMI. In 
step 1, we fitted separate multinomial logistic regression 
models to examine associations between each obesity-re-
lated disorder and bowel pattern group with adjustment 
for demographics, smoking and alcohol consumption. In 
step 2, we added BMI to each model to examine whether 
each obesity-related disorder was independently asso-
ciated with bowel pattern after controlling for BMI. In 
step 3, we included BMI with demographics and all six 
obesity-related disorders in a single model to examine 
whether individual obesity-related disorders were inde-
pendently associated with bowel patterns after adjusting 
for the other obesity-related disorders. Associations with 
bowel pattern were evaluated using adjusted ORs and 
95% CI, estimated by comparing participants with diar-
rhoea or normal bowel patterns to those with constipa-
tion. All statistical analyses were performed using the SAS 
software V.9.4. Two-sided p values <0.05 were regarded as 
significant.
resuLts
In NHANES 2005–2010, there were 17 132 participants 
>20 years of age, of whom 16 539 (97%) underwent an 
interview and medical exam. Among those, 2052 (12.4%) 
were excluded for missing questionnaire items on stool 
consistency/frequency, 93 (0.5%) were excluded for 
opioid-induced constipation, and 981 (5.9%) were 
excluded for missing information on covariates, leaving 
a total of 13 413 participants in the analytic sample 
(figure 1). Excluded subjects were more likely to be 
non-Hispanic black; to be former or never drinkers; to 
have cardiovascular disease, NAFLD, or diabetes; and 
were less likely to be married or living with a partner.
In the analytic sample, mean age was 46.7 (95% CI 46.0 
to 47.4) years, 51% were women and 71% were Cauca-
sian. Overall weighted prevalence was 84.5% for normal 
bowel patterns, 8.9% for constipation and 6.6% for diar-
rhoea. There were significant differences in age, sex, 
race/ethnicity, socioeconomic status, smoking status and 
alcohol consumption across groups (table 1).
As shown in table 1, those with diarrhoea had the 
highest mean age and were more likely to be Mexican 
Americans/Hispanics; widowed/divorced/separated; 
have less than a high school education; past or current 
smokers; and former drinkers than those with constipa-
tion. Those with normal bowel patterns were more likely 
to be non-Hispanic Whites; men; married/living with a 
partner; and have more than a high school education 
than those with diarrhoea or constipation. Those with 
constipation were more likely to be non-Hispanic blacks; 
women; never married; have a high school graduate/
general educational development or equivalent; have 
never smoked; or lifetime alcohol abstainers than those 
with normal bowel patterns or diarrhoea.
BMI and bowel pattern group
Mean BMI for the overall cohort was 28.7 kg/m2 (95% 
CI 28.5 to 28.9) and was associated with bowel pattern 
groups, being highest in those with diarrhoea (30.3 kg/
m2, 95% CI 29.7 to 30.9) and lowest in those with consti-
pation (27.8 kg/m2, 95% CI 27.3 to 28.3). This association 
remained significant after adjusting for demographics, 
smoking status, and alcohol consumption, and other 
obesity-related disorders (p<0.001). With every five addi-
tional point increase in BMI, there was a 17% increase 
in the estimated odds of having diarrhoea relative to 
having normal bowel pattern (OR=1.17, 95% CI 1.10 to 
1.25) and a 32% increase in the odds of having diarrhoea 
relative to having constipation (OR=1.32, 95% CI 1.23 to 
1.41).
obesity-related disorders by bowel pattern group
Overall prevalence of MS (table 1) was 30.0% (95% CI 
28.6 to 31.4) with a higher prevalence (p<0.001) observed 
in those with diarrhoea (36.0%, 95% CI 31.5 to 40.6) 
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Figure 1 National Health and Nutrition Examination Surveys 2005–2006, 2007–2008 and 2009–2010 patient cohort and 
analytic sample.
than with constipation (26.1%, 95% CI 22.4 to 29.8) or 
normal bowel patterns (29.9%, 95% CI 28.7 to 31.2). MS 
was associated with BMI. Participants with MS had a mean 
BMI of 32.8 (95% CI 32.5 to 33.1), which was significantly 
higher than those without MS (mean BMI of 26.9 (95% 
CI 26.7 to 27.1); p<0.001). The association between MS 
and bowel pattern group was reduced after adjustment 
(table 2) for demographic features, smoking and alcohol 
consumption, mainly because of the confounding effect 
of age, as older age was associated with both MS and diar-
rhoea. MS was associated with a statistical trend showing 
an increase in the odds of diarrhoea versus constipation 
(OR=1.271, 95% CI 0.970 to 1.666). The inclusion of BMI 
in the model further reduced the association between MS 
and bowel symptom group, resulting in a non-significant 
OR of 0.879 (95% CI 0.673 to 1.149) for having diarrhoea 
versus constipation.
Overall prevalence of presumed NAFLD (table 1) was 
higher with diarrhoea (12.9%, 95% CI 9.8 to 15.9) than 
with constipation (9.0%, 95% CI 7.0 to 11.0) or normal 
bowel patterns (9.5%, 95% CI 8.7 to 10.4). Participants 
with NAFLD had a mean BMI of 30.9 (95% CI 30.4 to 31.4), 
which was higher than those without NAFLD (mean BMI 
of 28.4 (95% CI 28.2 to 28.6)). After adjusting for demo-
graphics, smoking, alcohol consumption, BMI and other 
obesity-related disorders, this association was still signifi-
cant, with NAFLD associated with an increased odds of 
diarrhoea versus normal bowel patterns (OR=1.340, 95% 
CI 1.007 to 1.784) or constipation (OR=1.445, 95% CI 
1.028 to 2.031).
Each of the other four obesity-related disorders was 
associated with bowel patterns in the unadjusted analysis 
(p<0.05). Like MS, these associations were weakened 
or lost (table 2) with the adjustment of demographics, 
smoking and alcohol consumption. Additional adjust-
ment for BMI further weakened these associations. After 
adjusting for all covariates (demographics, smoking, 
alcohol consumption, BMI, other obesity-related disor-
ders), associations of diarrhoea with both diabetes and 
sleep disorders remained significant. Those with diabetes 
were more likely to have diarrhoea versus normal bowel 
patterns (OR=1.260, 95% CI 1.042 to 1.523). Those 
with a sleep disorder were more likely to have diarrhoea 
versus normal bowel patterns (OR=1.378, 95% CI 1.025 
to 1.853) or constipation (OR=1.459, 95% CI 1.006 to 
2.118).
exploratory analyses after adjustment for anti-diabetic 
medications
Additional analyses were conducted to evaluate whether 
bowel pattern group was associated with the use of 
anti-diabetic medications and how adjusting for anti-di-
abetic medications affected the study findings. In the 
analytic sample, 4.5% of participants used anti-diabetic 
medications including metformin, acarbose and exen-
atide. Frequencies were 3.3%, 4.3% and 9.0% for those 
with constipation, normal bowel patterns and diarrhoea, 
respectively (p<0.001). Relationships between bowel 
patterns and each obesity-related disorder were exam-
ined using multinomial logistic regression through 
sequential modelling to control for demographics, BMI, 
other obesity-related disorders and use of anti-diabetic 
medications. The observed associations of bowel pattern 
group with BMI (p<0.001) remained significant even 
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Table 1 Participant demographics and clinical characteristics by bowel pattern group








% 95% CI % 95% CI % 95% CI
Age, years (mean) 46.7 45.9 to 47.4 44.4 43.4 to 45.4 50.5 49.2 to 51.9
Women 48.2 47.2 to 49.1 74.6 71.7 to 77.6 56.2 52.3 to 60.1
BMI, kg/m2 (mean) 28.6 28.4 to 28.9 27.8 27.3 to 28.3 30.3 29.7 to 30.9
BMI class
Underweight or normal weight 31.2 29.6 to 32.8 38.3 34.6 to 42.1 25.6 21.7 to 29.4
Overweight 34.2 33.0 to 35.5 32.5 29.5 to 35.5 31.1 27.6 to 34.7
Class I obesity 20.2 19.2 to 21.2 15.5 13.3 to 17.7 19.8 16.2 to 23.5
Class II obesity 8.7 7.9 to 9.4 8.3 6.0 to 10.6 13.5 11.0 to 15.9
Class III obesity 5.7 5.2 to 6.3 5.4 4.0 to 6.7 10.0 7.1 to 12.9
Race
Non-Hispanic White 72.5 69.1 to 75.9 64.4 58.4 to 70.3 67.2 60.8 to 73.6
Non-Hispanic Black 9.7 (8.0 to 11.4) 16.3 12.5 to 20.2 11.7 9.2 to 14.2
Hispanic 12.3 10.0 to 14.7 14.6 11.1 to 18.1 15.6 11.3 to 19.8
Other 5.5 4.6 to 6.3 4.7 2.7 to 6.7 5.5 3.5 to 7.6
Marital status
Married, living with partner 66.1 64.3 to 67.9 60.3 56.7 to 64.0 65.4 61.7 to 69.1
Widowed/divorced /separated 17.5 16.6 to 18.5 20.7 18.0 to 23.4 22.1 19.3 to 24.9
Never married 16.3 15.0 to 17.7 19.0 16.1 to 21.8 12.5 9.8 to 15.2
Education
Less than high school 16.9 15.2 to 18.5 23.1 19.8 to 26.4 27.1 23.4 to 30.9
High school or GED 23.5 22.2 to 24.8 28.7 26.0 to 31.4 24.3 20.2 to 28.3
More than high school 59.6 57.3 to 61.9 48.2 44.0 to 52.5 48.6 43.8 to 53.4
Smoking
Never 52.6 50.8 to 54.4 59.3 55.3 to 63.2 45.7 41.4 to 49.9
Past smoker 25.4 24.1 to 26.8 19.0 16.4 to 21.5 28.0 24.5 to 31.6
Current smoker 22.0 20.6 to 23.4 21.8 18.2 to 25.3 26.3 22.5 to 30.0
Alcohol
Lifetime abstainer 10.2 9.0 to 11.3 16.1 13.3 to 19.0 12.0 9.5 to 14.5
Former drinker 15.7 14.4 to 17.0 17.7 15.2 to 20.3 21.6 16.8 to 26.5
Moderate 41.8 40.1 to 43.4 43.1 39.9 to 46.4 37.2 33.6 to 40.7
Excessive 32.4 30.7 to 34.0 23.0 20.3 to 25.7 29.2 24.8 to 33.6
Metabolic syndrome 29.9 28.7 to 31.2 26.1 22.4 to 29.8 36.0 31.5 to 40.6
Cardiovascular disease* 7.7 6.9 to 8.4 7.9 6.1 to 9.7 11.5 8.6 to 14.3
Diabetes 9.7 8.9 to 10.5 9.2 7.3 to 11.2 15.7 12.9 to 18.5
NAFLD† 9.5 8.7 to 10.4 9.0 7.0 to 11.0 12.9 9.8 to 15.9
Sleep disorder 7.3 6.7 to 7.9 5.9 4.3 to 7.4 11.4 8.7 to 14.2
Cancer‡ 8.7 7.8 to 9.6 9.6 7.5 to 11.7 12.4 9.9 to 15.0
Comparisons performed using analysis of variance for continuous variables and Rao-Scott χ2 test for categorical variables.
*P value=0.002.
†P value=0.035.
‡P value=0.005; all other p values <0.001.
BMI, body mass index; GED, general educational development; NAFLD, non-alcoholic fatty liver disease.
after adjustment for all covariates and anti-diabetic medi-
cations. Associations of bowel pattern groups with sleep 
disorders and NAFLD remained significant, while the 
association of bowel pattern group with diabetes was no 
longer significant. Those with a sleep disorder were more 
likely to have diarrhoea versus normal bowel patterns 
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Table 2 Adjusted associations between bowel pattern group and obesity-related disorders
Step 1 models Step 2 models Step 3 models
OR 95% CI OR 95% CI OR 95% C
Metabolic syndrome Normal versus 
Constipation
1.188 0.967 to 1.458 1.019 0.822 to 1.263 1.058 0.838 to 1.33
Diarrhoea versus 
Constipation
1.271 0.970 to 1.666 0.879 0.673 to 1.149 0.836 0.635 to 1.102
Diarrhoea versus 
Normal
1.070 0.883 to 1.297 0.863 0.689 to 1.082 0.790 0.619 to 1.008
Cardiovascular disease Normal versus 
Constipation
0.778 0.584 to 1.038 0.756 0.569 to 1.006 0.767 0.579 to 1.018
Diarrhoea versus 
Constipation
0.916 0.620 to 1.355 0.851 0.578 to 1.251 0.826 0.558 to 1.222
Diarrhoea versus 
Normal
1.177 0.904 to 1.533 1.125 0.865 to 1.462 1.077 0.823 to 1.408
Diabetes Normal versus 
Constipation
1.013 0.788 to 1.302 0.905 0.705 to 1.163 0.918 0.688 to 1.224
Diarrhoea versus 
Constipation
1.385 1.036 to 1.852 1.091 0.809 to 1.471 1.156 0.828 to 1.615
Diarrhoea versus 
Normal
1.367 1.138 to 1.642 1.205 1.015 to 1.430 1.260 1.042 to 1.523




1.136 0.862 to 1.49 1.083 0.825 to 1.42 1.078 0.823 to 1.412
Diarrhoea versus 
Constipation
1.597 1.129 to 2.26 1.437 1.021 to 2.02 1.445 1.028 to 2.031
Diarrhoea versus 
Normal
1.406 1.053 to 1.878 1.326 0.994 to 1.769 1.340 1.007 to 1.784
Sleep disorder Normal versus 
Constipation
1.142 0.866 to 1.505 1.034 0.772 to 1.384 1.059 0.787 to 1.424
Diarrhoea versus 
Constipation
1.802 1.253 to 2.590 1.440 0.993 to 2.089 1.459 1.006 to 2.118
Diarrhoea versus 
Normal
1.578 1.168 to 2.131 1.393 1.032 to 1.880 1.378 1.025 to 1.853
Cancer Normal versus 
Constipation
0.768 0.593 to 0.996 0.770 0.594 to 0.996 0.780 0.604 to 1.008
Diarrhoea versus 
Constipation
0.973 0.674 to 1.403 0.980 0.680 to 1.413 0.992 0.690 to 1.426
Diarrhoea versus 
Normal
1.266 0.987 to 1.624 1.274 0.994 to 1.633 1.271 0.988 to 1.636
Comparisons based on multinomial logistic regression.
(OR=1.373, 95% CI 1.021 to 1.845) or constipation 
(OR=1.452, 95% CI 1.000 to 2.110). Those with NAFLD 
were more likely to have w diarrhoea versus normal bowel 
patterns (OR=1.344, 95% CI 1.011 to 1.787) or constipa-
tion (OR=1.450, 95% CI 1.030 to 2.042).
dIscussIon
This study is the first to examine the association of 
bowel patterns with MS and NAFLD among a repre-
sentative sample of US adults. As associations between 
obesity and diarrhoea have previously been well 
described,4–6 20 it is not surprising that our findings 
demonstrate an association between BMI and diarrhoea. 
Possible mechanisms explaining this association include 
alterations in regional GI transit,21 22 bile acid malab-
sorption, increased intestinal permeability, or low-grade 
inflammation (reviewed in23). Changes in the intestinal 
microbiome have also been associated with functional 
bowel disorders, obesity and MS24 and may represent a 
common pathophysiological exposure. In this cross-sec-
tional study, although MS was more prevalent in indi-
viduals reporting diarrhoea, this association was not 
statistically significant and was weakened after adjusting 
for BMI, suggesting that MS is not independently 
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associated with diarrhoea. This is not unexpected 
given that bowel disorders and MS are both clinically 
heterogeneous conditions. As BMI is correlated with 
waist circumference and other components of MS, it is 
not unexpected that the relationship between MS and 
bowel patterns is no longer significant after adjusting 
for BMI. However, this association is still an important 
one to explore as several studies have demonstrated the 
concept of ‘normal weight obesity’ that is associated with 
MS, insulin resistance, or other obesity-related disor-
ders.25 26 In contrast, examination of other obesity-re-
lated disorders revealed that NAFLD was independently 
associated with diarrhoea versus normal bowel patterns 
or constipation even after adjusting for BMI and other 
obesity-related disorders. Presence of diabetes was also 
independently associated with diarrhoea versus normal 
bowel patterns while presence of a sleep disorder was 
independently associated with diarrhoea versus normal 
bowel patterns or constipation.
The association between diarrhoea and NAFLD is 
important to note and may help guide future studies of 
the mechanisms that link obesity or increased BMI with 
diarrhoea. For example, bile-acid mediated mechanisms 
may be of particular interest as the role of bile acids has 
been implicated in the pathophysiology of both chronic 
diarrhoea and NAFLD. Clinical studies have identified 
genetic variations in the bile acid receptor, Takeda G-pro-
tein-coupled receptor-5 (TGR5 or GPBAR1) that may 
contribute to altered transit in lower functional bowel 
disorders.27 Activation of TGR5 may also have important 
effects on glucagon-like peptide-1 associated metabolic 
regulation28 relevant to NAFLD. Impaired production 
of fibroblast growth factor 19 (FGF19), which regulates 
hepatic synthesis of bile acids, has been proposed as a 
mechanisms for bile acid diarrhoea29 and has also been 
implicated in the pathogenesis of NAFLD.30 Further-
more, bile acid-activated farnesoid X receptor agonists, 
such as obeticholic acid, have been studied for the treat-
ment of both bile acid diarrhoea and in NAFLD. Among 
patients with primary bile acid diarrhoea, obeticholic 
acid was associated with increased median fasting FGF-19 
and improvements in bowel functions.31 Meanwhile, 
in a multicentre double-blind randomised controlled 
trail among patients with non-alcoholic steatohepatitis, 
obeticholic acid improved biochemical and histological 
features of NASH compared with placebo.32
Important to note is that bile acid diarrhoea may be an 
aetiology in up to 50% of patients with chronic diarrhoea33 
and has been positively associated with BMI.2 In a recent 
retrospective study, Appleby et al reported an increased 
prevalence of fatty liver disease in bile acid diarrhoea,8 
although confounding by BMI could not be excluded. A 
subsequent prospective study of NAFLD patients found 
associations between increased hepatic bile acid synthesis 
with diarrhoea and increased NAFLD fibrosis score10 as 
well as a higher than expected incidence of chronic diar-
rhoea (25%). However, no control group was available 
for comparison. In our analysis, the association between 
NAFLD and diarrhoea in a large nationally represen-
tative sample of the general US population remained 
significant even after adjusting for BMI and other obesi-
ty-related disorders although the prevalence of bile acid 
diarrhoea and other mechanisms for bowel dysfunc-
tion could not be determined from the cross-sectional 
NHANES data. Taken together, findings from our study 
add to the body of evidence suggesting that NAFLD and 
chronic diarrhoea may be independently linked and that 
further attention to the gut-liver axis may be required 
among patients with common bowel disorders such as 
functional diarrhoea or IBS. These potential relation-
ships, however, are likely complex and bidirectional and 
may involve additional factors such as the GI microbiome 
and transit. It should further be noted that the magni-
tude of the observed associations between NAFLD and 
bowel patterns in our study were modest, suggesting 
that multiple factors contribute to the pathogenesis of 
NAFLD and bowel symptoms. However, the strength 
of these associations may have been diminished by the 
broad definitions of diarrhoea and constipation used in 
this study, which likely contributed to the heterogeneity 
of the bowel pattern groups. Thus, further prospective 
investigation of intraluminal bile acids, NAFLD and 
diarrhoea are warranted to validate these associations. 
Although it is possible that associations between NAFLD 
and diarrhoea may have been confounded by residual 
factors such as medication use (eg, lactulose for hepatic 
encephalopathy), only 10 individuals in the analytic 
sample were identified as having NASH cirrhosis. Thus, 
confounding by factors associated with clinical features 
of cirrhosis were unlikely to have an important effect.
Associations between diarrhoea and sleep disor-
ders including insomnia, sleep apnoea and restless leg 
syndrome in this population-based study may support 
previous hypotheses involving the role of the brain-gut 
axis in lower functional bowel disorders. Sleep distur-
bances including abnormal REM sleep,34 sleep apnoea35 
and sleep impairment36 have been associated with IBS. 
Contrary to our findings, in one prior study,36 sleep 
impairment was more common in constipation-predom-
inant IBS patients than in diarrhoea-predominant IBS. 
Observed associations between diarrhoea and diabetes 
in our study are consistent with a recently published 
study37 which reported an increased prevalence of 
chronic diarrhoea in diabetics compared with non-dia-
betics using data from the 2009 to 2010 NHANES dataset. 
It is possible that these associations may reflect the use 
of anti-diabetic medications such as metformin.38 To 
explore this question, we conducted additional analyses 
to evaluate whether the associations of bowel pattern 
group with obesity-related disorders were influenced 
by the use of anti-diabetic medications (eg, metformin, 
acarbose and exenatide) to demonstrate that although 
the association of bowel pattern group with diabetes was 
no longer significant, the associations of bowel pattern 
group with BMI, sleep disorders and NAFLD remained 
significant. Other potential mechanisms may include bile 
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acid malabsorption,39 bacterial overgrowth,40 autonomic 
neuropathy41 and consumption of artificial sweeteners. 
As presence of a sleep disorder or diabetes was based on 
self-report, further studies to confirm these findings and 
to evaluate the associations of specific types of sleep disor-
ders or diabetes type with bowel patterns will be required.
Our study has several limitations, including the 
cross-sectional nature of the NHANES data, reliance on 
self-report data with potential for recall bias, lack of infor-
mation on presence of celiac disease or inflammatory 
bowel disease (available only for the 2009–2010 cycle for 
subjects ages 20–69), and lack of data on symptom dura-
tion or other GI conditions such as microscopic colitis. 
Although definitions for constipation and diarrhoea 
were based on prior NHANES publications,4 15 16 these 
definitions are not universally agreed on. In this study we 
defined constipation and diarrhoea based on responses 
to the BHQ. The BHQ is a broad tool assessing only 
stool consistency and frequency, and it does not assess 
for other symptoms such as abdominal pain. Therefore, 
we were unable to apply Rome IV diagnostic criteria. 
Furthermore, data on whether participants underwent 
additional diagnostic testing for their bowel symptoms 
with blood tests, stool tests, colonoscopy or radiographic 
imaging, or other secondary tests where indicated was 
not available.42 Hence, the generalisability of our find-
ings to patients with IBS, functional constipation and 
functional diarrhoea may be limited. Some patients with 
NAFLD may have normal liver tests, and abnormal liver 
test are not required to make a diagnosis of NAFLD. In 
this cohort, we did not have histological or radiological 
confirmation of a clinical diagnosis of NAFLD. Together, 
these factors may have led to underestimation of the prev-
alence of NAFLD. In addition, analyses were not adjusted 
for multiple testing and our findings are more suggestive 
than definitive. However, the results are informative and 
hypothesis generating as this is the first population-based 
study to report an association between NAFLD and 
chronic diarrhoea that is independent of BMI.
In summary, among a representative sample of US 
adults, results of our population-based cross-sectional 
analysis support previously reported associations between 
BMI or obesity and diarrhoea that are not clearly 
explained by eating behaviours or socioeconomic charac-
teristics in prior studies.5 Although there does not seem 
to be a significant association between MS and bowel 
patterns independent of BMI, the results suggest that 
diarrhoea may be independently linked to NAFLD, which 
may warrant further prospective evaluation of shared 
aetiological mechanisms between these two highly prev-
alent conditions.
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